Trial ID or NCT#

NCT02677324

Status

not recruiting iconNOT RECRUITING

Purpose

This research study is studying a targeted therapy as a possible treatment for relapsed or refractory Waldenstrom's Macroglobulinemia (WM). This study is using the study intervention ABT-199.

Official Title

Phase II Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Ranjana Advani
Ranjana Advani
Medical oncologist, Lymphoma specialist
Saul A. Rosenberg, MD, Professor of Lymphoma

Contact us to find out if this trial is right for you.

CONTACT

CCTO
(650) 498-7061